PB 37 of 2025
National Health (April 2025 Price Reductions) (Exercise of Ministerial discretion) Determination (No.1) 2025
National Health Act 1953
I, Rebecca Richardson, as delegate of the Minister for Health and Aged Care, make the following determination.
Dated 26 March 2025
REBECCA RICHARDSON
Assistant Secretary
Pricing and PBS Policy Branch
Technology Assessment and Access Division
Health Resourcing Group
Department of Health and Aged Care
1 Name
(1) This instrument is the National Health (April 2025 Price Reductions) (Exercise of Ministerial discretion) Determination (No.1) 2025.
(2) This instrument may also be cited as PB 37 of 2025.
2 Commencement
(1) Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.
Commencement information | ||
Column 1 | Column 2 | Column 3 |
Provisions | Commencement | Date/Details |
1. The whole of this instrument | 1 April 2025 |
|
Note: This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.
(2) Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.
3 Definition
Note: A number of expressions used in this instrument are defined in Part VII the Act.
In this instrument:
Act means the National Health Act 1953.
reduction day in this instrument refers to 1 April 2025.
4 Authority
This instrument is made under subsections 99ACF(3) and 99ADHB(6) of the Act.
5 Brand of pharmaceutical item not subject to a price reduction
- I determine, under paragraph 99ACF(3)(a) of the Act, that the approved ex-manufacturer price, and each of the claimed prices (if applicable) of each brand of pharmaceutical item specified in column 2 as an item in the table in Schedule 1 is not reduced under a provision mentioned in item 3A or item 4A of the table in subsection 99ACF(1) of the Act, as appropriate, in relation to the reduction day.
- I determine, under subsection 99ADHB(6) of the Act, that the approved ex-manufacturer price, and each of the claimed prices (if applicable) of each brand of pharmaceutical item specified in column 2 as an item in the table in Schedule 2 is not reduced under a provision mentioned in subsection 99ADHB(2) of the Act, as appropriate, in relation to the reduction day.
Schedule 1 — Brands of pharmaceutical items with approved ex-manufacturer price not reduced
Column 1 | Column 2 | |||
Item | Brand of Pharmaceutical Item | |||
| Drug | Form | Manner of administration | Brand(s) |
1 | Midazolam | Oromucosal solution (as maleate) 5 mg in 0.5 mL single use pre-filled oral syringe | Buccal | Zyamis |
2 | Midazolam | Oromucosal solution (as maleate) 7.5 mg in 0.75 mL single use pre-filled oral syringe | Buccal | Zyamis |
3 | Midazolam | Oromucosal solution (as maleate) 10 mg in 1 mL single use pre-filled oral syringe | Buccal | Zyamis |
4 | Triglycerides, long chain with glucose polymer | Oral liquid 1 L, 6 (ProZero) | Oral | ProZero |
5 | Ustekinumab | Injection 45 mg in 0.5 mL | Injection | Stelara |
6 | Ustekinumab | Solution for I.V. infusion 130 mg in 26 mL | Injection | Stelara |
Schedule 2 — Brands of pharmaceutical items with approved ex-manufacturer price not reduced
Column 1 | Column 2 | |||
Item | Brand of Pharmaceutical Item | |||
| Drug | Form | Manner of administration | Brand(s) |
1 | Tenofovir with emtricitabine | Tablet containing tenofovir disoproxil fumarate 300 mg with emtricitabine 200 mg (s19A) | Oral | Emtricitabine and Tenofovir Disoproxil Fumarate 200mg/300mg Tablets (Laurus Labs, USA) |